We previously identified in fetal rat serum a component capable of specifically binding radiolabeled insulinlike growth factor type II (IGF-II) that is considerably larger than both the fetal (40 kDa) and the adult (150 kDa (19-days gestation) and in sera from 3-, 10-, and 20-day-old rats, the concentrations of receptor protein were similar (1-5 gug/ml). The level of the type II IGF receptor in serum declined dramatically between age 20 and 40 days, but the receptor was still measurable at age 12 mo. We conclude that the type H IGF receptor is present in rat serum and is developmentally regulated.
ABSTRACT
We previously identified in fetal rat serum a component capable of specifically binding radiolabeled insulinlike growth factor type II (IGF-II) that is considerably larger than both the fetal (40 kDa) and the adult (150 kDa) carrier proteins. We now present immunologic and affinity crosslinking data to (19-days gestation) and in sera from 3-, 10-, and 20-day-old rats, the concentrations of receptor protein were similar (1-5 gug/ml). The level of the type II IGF receptor in serum declined dramatically between age 20 and 40 days, but the receptor was still measurable at age 12 mo. We conclude that the type H IGF receptor is present in rat serum and is developmentally regulated.
The insulin-like growth factors (IGF-I and IGF-II), which show extensive amino acid sequence homology with insulin (1) , are mitogens for cells in culture, frequently acting in concert with other growth factors (2) . IGF-I mediates the anabolic action of pituitary growth hormone in vivo (3) . The in vivo role for IGF-II is less clear, but the observation that IGF-II concentration is high in fetal rat serum, with a decline postnatally, has led to the proposal that IGF-II may be important for fetal growth in the rat (4, 5) .
IGF-I and IGF-II bind to high-affinity receptors present on many cells and tissues (6) (14) . The primary structure of the type II IGF receptor has not been elucidated.
There are also two classes of serum IGF carrier proteins (15), one from adult serum that is growth hormone dependent and immunoglobulin sized (150-kDa carrier protein) (16) , and the other class predominates in fetal serum and is slightly smaller than albumin (40-kDa carrier protein) (17) . We previously identified in fetal rat serum a component capable of specifically binding 1251I-labeled IGF-II (125I-IGF-II) that is considerably larger than the 150-and 40-kDa carrier proteins (17) . We now present immunologic and affinity crosslinking data to show that this binding species is the type II IGF receptor and provide evidence that circulating type II IGF receptor is developmentally regulated, being high in fetal and neonatal sera and then rapidly declining after day 20. MATERIALS AND METHODS Peptides and Radioligands. Rat IGF-II (multiplication stimulating activity, MSA-III-2) was purified to homogeneity from BRL 3A-conditioned medium according to method B of Greenstein et al. (18) . [Thr5]IGF-I and insulin were purchased from AmGen (Thousand Oaks, CA) and Sigma. IGF-I and IGF-II were iodinated by a modified chloramine-T procedure (19) (23), was used as a standard. Protein content of the purified receptor was measured by a modified Lowry method (24) . Phase Separation of Rat Placental Membrane Type I Receptor in Triton X-114. Triton X-114 (Sigma) was precondensed three times to obtain a more homogenous preparation (25) . Phase separation was performed as described (25, 26) . A microsomal membrane preparation from rat placenta was solubilized in 1% Triton X-114 in 0.02 M Tris-HCl, pH 7.4/0.15 NaCl (4 mg of membrane protein per ml of detergent) at 4°C for 1 hr and centrifuged at 100,000 x g for 90 min. A 0.3-ml aliquot of the supernatant was layered on 0.15 ml of 6% (wt/vol) sucrose/0.06% Triton X-114/Tris/NaCl, warmed to 35°C for 3 min, and centrifuged at 340 X g for 3 min at 22°C. The (Fig. 1 Left) . The growth hormone-dependent 150-kDa carrier protein appeared postnatally between day 10 and 20 and predominated over the 40-kDa carrier protein in the adult rat as reported (16, 17) . To characterize the 1251_IGF-II binding activity in the void volume of the Sephadex G-200 column, the relative ability of unlabeled IGF-I, IGF-II, and insulin to compete for binding of 1251-IGF-II was measured (Fig. 1 Right) . In addition, we used a polyclonal rabbit antiserum (no. 3637) that specifically blocks the binding of 1251-IGF-II to the type II IGF receptor (21) . IGF-II was more potent than IGF-I, and insulin did not compete for binding of 125I-IGF-II. In addition, the anti-type II receptor IgG completely blocked 1251-IGF-II binding to VO material from fetal and neonatal rat sera. The anti-type II IGF receptor IgG only partially inhibited 125I-IGF-II binding to the V0 pool from the sera of 40-day-old and 12-mo-old rats, consistent with contamination of those V0 pools with 150-kDa carrier protein.
When binding of 1251-IGF-I to individual fractions from the Sephadex G-200 gel filtrations of 10-and 40-day-old rats was measured, only minimal binding activity was detected ( (Fig. 2) . Formation of the 240-kDa radioligand-receptor complex was prevented by incubation with unlabeled IGF-II and anti-type II receptor
IgG 3737, whereas insulin and control IgG did not block formation of the type II receptor complex. When NaDod-S04/PAGE was performed without disulfide bond reduction, the size of the radioligand-receptor complex decreased to 210 kDa (data not shown), analogous to the behavior of the membrane-associated type II IGF receptor (7, 10) . Quantitation of the Serum Type II IGF Receptor: Developmental Regulation. Gel filtration of fetal and postnatal serum on Sephadex G-200 and measurement of 125I-IGF-II binding in the V0 fractions (Fig. 1) suggested that the amount of type II receptor was higher in fetal and neonatal sera than in sera from older animals. To measure the amount of type II receptor in these sera, we used two methods-Scatchard analysis of the binding of IGF-II and immunoblotting with anti-type II IGF receptor antiserum and highly purified type II receptor as standard. Scatchard analysis of IGF-II binding to the Sephadex G-200 VO pool from fetal and 3-, 10-, and 20-day-old rat sera yielded a straight line consistent with a single class of binding sites. Assuming a binding stoichiometry of 1:1, we calculated the amount of receptor protein to be 4, 2, 7, and 2 ,ug/ml, respectively. In addition, immunoblotting was done on both untreated sera (data not shown) and aliquots of the Sephadex G-200 VO pools from rats at different ages (Fig. 3) . Immunoquantitation revealed a developmental pattern; in fetal rat serum (19- Finally, we examined the relative preference of the intact membrane-derived type II receptor for a detergent-rich versus a detergent-poor environment by utilizing the technique of phase separation in Triton X-114 (25, 26) . Typically, intrinsic membrane proteins are recovered from the detergent-rich phase (25) . However, when rat placental membranes were solubilized and phase separation was carried out, 125I-IGF-II binding activity was predominantly measured in the detergent-poor phase; binding of 1251-IGF-II to the detergent-poor phase was 3-to 4-fold greater than binding to the detergent-rich phase (data not shown). Immunoblotting of detergent-poor and detergent-rich phases also revealed a 3-to 4- The presence of other growth factor receptors in serum or in conditioned medium from cell cultures has been reported. Human epidermoid carcinoma A431 cells secrete a 105-kDa protein that is the extracellular domain of the epidermal growth factor receptor (27) . A truncated form of the interleukin 2 (IL-2) receptor is secreted by activated T-cell lines and peripheral mononuclear cells (28) . The IL-2 receptor is also present in human serum, and there is a 100-fold increase in levels of the receptor protein in sera from patients with T-cell leukemia (28) . A specific growth hormone binding protein has been reported in rabbit and human sera (29, 30) . In the rabbit, there is evidence for immunologic identity between the serum growth hormone binding protein and a membrane growth hormone receptor.** IM-9 lymphocytes have been shown to release into the culture medium growth hormone and insulin binding components, presumably intact receptors or receptor fragments (31, 32) . In the case of the soluble forms of the epidermal growth factor and IL-2 receptors, there is evidence that these truncated forms represent the extracellular domains of the membrane receptors (27, 28) . Our affinity crosslinking and immunoblotting data show that the serum type II IGF receptor is -10 kDa smaller than the intact receptor from rat placental membranes, raising the possibility that the serum type II IGF receptor may also represent the extracellular domain. However, a similar size difference has been reported between two membrane type II receptors from different tissues in the rat (adipocytes and liver) (8) . If the serum type II IGF receptor is analogous to the truncated epidermal growth factor and IL-2 receptors and represents the extracellular domain, this means that the cytoplasmic domain of the type II receptor is relatively small.
In fetal and neonatal rat sera, the concentration of the type II IGF receptor is at least several micrograms per milliliter
We previously described a component in fetal rat serum capable of specifically binding '25I-IGF-II that is considerably larger than the 150-and 40-kDa IGF carrier proteins (17 What is the function ofthe serum type II IGF receptor? The serum type II IGF receptor is not a significant carrier of circulating IGF-II in fetal rats; <3% of serum IGF-II is found associated with the type II receptor (17) . This is, in part, explained by the lower concentration of serum type II IGF receptor (10 nM) compared with the 40-kDa carrier protein (200-600 nM) (17) . Nonetheless, if present in extracellular fluid, it is possible that the type II IGF receptor could modulate the action of IGF-II. In this regard, it is of interest that the serum type II IGF receptor is developmentally regulated, being high in fetal and neonatal sera and then declining rapidly after day 20 . This approximates the developmental pattern of IGF-II itself (4, 5) .
